CLEARSIDE BIOMEDICAL INC (CLSD)

Friday 4/19 Insider Buying Report: CLSD, ULS

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors...

7 Top Stocks Under $7

Stocks under $7 have greater potential for substantial gains because they start off with lower valuations. Here are some of the best now.

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery...

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Industry Veteran with Extensive Experience in Retinal Disease Research and Strong Track Record in Advancing Programs Through Clinical Development...

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data...

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Biotech penny stocks represent one heckuva risk. However, if the stars align, you could be talking some serious money.

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company...

Clearside Biomedical says CEO Lasezkay sells 18K shares (NASDAQ:CLSD)

Clearside Biomedical's CEO sold 18K shares to meet tax obligations, while insider trading saw a net purchase of 135.8K shares in the past 3 months.

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD ...

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor -

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

Robust Safety Profile and Encouraging Efficacy Data Utilizing SCS Microinjector® Featured in Multiple Data Presentations...

BioCryst joins Clearside Biomedical for diabetic eye disease

BioCryst Pharmaceuticals (BCRX) and Clearside Biomedical (CLSD) ink a licensing deal to develop a more effective treatment for diabetic macular edema. Read more here.

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

Clearside Biomedical announced that multiple oral & poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Mtg....

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ...

Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023

ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

3 Cheap Stocks to Buy Under $1 in October 2023

If you want extreme returns and can handle the prospects of utterly devastating losses, these cheap stocks under $1 might entice.

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

- Excellent Safety Profile, Stable Vision, and Reduced Frequency of Injections Observed for up to 6 months – - ODYSSEY Phase 2b Clinical Trial...

Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China

- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) - ALPHARETTA, Ga., Oct. 04, 2023 (GLOBE...

Clearside Biomedical to Participate in a Panel Discussion at the JonesTrading 2023 Healthcare Summit

ALPHARETTA, Ga., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of...

Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference

ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery...

Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform...